Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | EED | O75530 | 8/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 8/20 | 0.40 |
| ▸ | SUZ12 | Q15022 | 8/20 | 0.40 |
| ▸ | AEBP2 | Q6ZN18 | 8/20 | 0.40 |
| ▸ | EZH1 | Q92800 | 3/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 15/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29180269 | 0.78 | EZH2 (0.39) | IDO1EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL16740904 | 0.78 | EZH2 (0.46) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL31729581 | 0.78 | EZH2 (0.46) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL13279572 | 0.76 | EZH2 (0.70) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL13279656 | 0.74 | EZH2 (0.45) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL16213153 | 0.73 | EED (0.57) | EEDRBBP4SUZ12AEBP2EZH2 | |
| SCHEMBL28466809 | 0.73 | EZH2 (0.41) | IDO1EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL24072862 | 0.72 | EZH2 (0.47) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL29613562 | 0.71 | EZH2 (0.60) | EEDRBBP4SUZ12AEBP2EZH1 | |
| SCHEMBL13276540 | 0.71 | EZH2 (0.60) | EEDRBBP4SUZ12AEBP2EZH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3470396-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| EP-3165520-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme Inc (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20160332969-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-11-17 | — | — | US | disclosed |
| US-9376422-B2 | Dihidropyridin-2-one benzamine compounds | Epizyme, Inc. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-2697198-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2697198-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142083-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2697198-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142513-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142083-A1 | Substituted Benzene Compounds | CYP1B1, TP53, VHL | IDO1 511/4885EED 1592/4885RBBP4 253/4885 |
| US-20160332969-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | IDO1 511/4885EED 1592/4885RBBP4 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.